EverHint – Dip Bounce V2 (Reclaim) – Top 15 Signals for Sep 18, 2026
Excerpt: 15 signals (from 39 total). Healthcare leads (16). price range $8-$240.
What This Signal Is
Production-ready dip-bounce strategy using reclaim pattern with Phase 2 market regime filters. Improved win rate from 40.42% (V1) to 50.18% (V2) with VIX and record high filters.
Entry Criteria:
- Minimum dip: 3.3% (open to intraday low)
- Minimum bounce: 1.0% from low
- Net change range: -2.0% to +0.3%
- Price above SMA(200)
- Minimum ADV: $40M
Holding period: 1-5 days | Risk level: Medium
Market Context
With the VIX sitting at 14.81 and declining sharply by over 4%, the market is signaling a notably calm volatility environment. For dip-bounce reclaim strategies, this is a double-edged dynamic — lower volatility reduces the magnitude of intraday swings, which can compress the reward potential on individual bounces, but it also means cleaner, less noisy price action that makes reclaim levels easier to identify and trust. Traders should calibrate expectations accordingly, targeting tighter, higher-probability setups rather than wide-range momentum plays.
The broader index picture reflects a modestly risk-on tone, with the Nasdaq leading gains at +0.39% while the Dow slightly underperforms at -0.18%. This mild divergence suggests growth and technology-adjacent sentiment is holding up better than value or cyclical exposure, pointing to selective rather than broad-based risk appetite. For dip-bounce signals, this environment favors setups where price has pulled back into a defined support zone and is reclaiming a key level, as the underlying trend remains constructive enough to support mean-reversion entries without requiring a strong macro tailwind.
Healthcare emerging as the top sector for today's signals aligns well with the current market temperament. Healthcare tends to attract rotation during periods of tempered volatility and cautious optimism, offering defensive growth characteristics that appeal when investors are risk-aware but not risk-off. With 39 total signals generated, the opportunity set is reasonably broad, and the concentration in Healthcare suggests sector-level momentum is supporting individual dip-bounce setups within that space — a favorable condition for the strategy's underlying thesis of reclaiming lost ground within an intact trend.
📊 Signals (15 of 39 total)
Ranked by dip magnitude (highest first)
| # | Ticker | Company | Sector | Price | Score | MCap |
|---|---|---|---|---|---|---|
| 1 | AXTI | AXT, Inc. | Technology | $70.03 | 0.37 | $3.6B |
| 2 | AUPH | Aurinia Pharmaceutical... | Healthcare | $16.90 | 0.28 | $2.2B |
| 3 | VOYG | Voyager Technologies, ... | Industrials | $35.87 | 0.27 | $2.2B |
| 4 | CDLR | Cadeler A/S | Industrials | $25.50 | 0.23 | $2.5B |
| 5 | MRNA | Moderna, Inc. | Healthcare | $154.04 | 0.22 | $61.1B |
| 6 | ABSI | Absci Corporation | Healthcare | $9.65 | 0.19 | $1.6B |
| 7 | TWST | Twist Bioscience Corpo... | Healthcare | $166.99 | 0.19 | $10.4B |
| 8 | ABCL | AbCellera Biologics Inc. | Healthcare | $12.63 | 0.19 | $3.9B |
| 9 | KMI | Kinder Morgan, Inc. | Energy | $31.84 | 0.18 | $70.9B |
| 10 | ILMN | Illumina, Inc. | Healthcare | $239.62 | 0.16 | $36.3B |
| 11 | AEHR | Aehr Test Systems | Technology | $93.49 | 0.16 | $3.0B |
| 12 | AMRX | Amneal Pharmaceuticals... | Healthcare | $18.71 | 0.15 | $6.0B |
| 13 | STM | STMicroelectronics N.V. | Technology | $50.18 | 0.14 | $44.8B |
| 14 | DHC | Diversified Healthcare... | Real Estate | $8.01 | 0.13 | $1.9B |
| 15 | BRKR | Bruker Corporation | Healthcare | $61.39 | 0.13 | $9.3B |
Field Notes
Sector concentration: Healthcare (16), Technology (8), Industrials (5)
Data coverage: 0.0% insider (7d), 0.0% congressional (30d), 0.0% earnings, 20.5% news (7d)
Peer Analysis
KMI (Kinder Morgan, Inc.): Leads 5 peers: ET ($21.14), TRP ($61.54), E ($54.62), EPD ($38.89), MPLX ($59.44)
MRNA (Moderna, Inc.): Leads 5 peers: TECH ($72.37), BMRN ($63.94), EXEL ($58.36), MDGL ($531.52), CAI ($29.98)
Recent Headlines
AMRX (Amneal Pharmaceuticals, Inc.)
- Amneal Announces FDA Approval and Launch of Lanreotide Injection
- Amneal receives FDA approval for generic lanreotide injection
KMI (Kinder Morgan, Inc.)
- Natural Gas Dominates U.S. Power Generation: 2 Midstream Stocks to Watch
Vlad's Take
Today's signals: Strong sector concentration in Healthcare (16 signals) suggests sector-specific rotation.
Trading tips for this strategy:
- Entry timing: Consider entering on next-day weakness or at previous day's close level
- Position sizing: Start small (1-2% of portfolio per signal)
- Stop loss: Below today's low (tight stops for mean reversion)
- Take profit: 3-5% bounce target, or previous day's high
- Time stop: Exit if no bounce in 1-3 days
Risk warning: Mean reversion can fail in strong downtrends - check broader market context
Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.
This is not financial advice. Market conditions change rapidly.
Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/
📢 Enjoying the updates? Liking, sharing, or subscribing helps bring this analysis to a wider audience.